PATENT CLAIM ANALYSIS

Application Number: 15936811
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "352000"]

Abstract:
The present disclosure relates generally to compounds and methods for inhibiting the enzymatic activity of lysine demethylase 4 (KDM4) and treating cancer. Provided herein are substituted pyridine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibiting lysine demethylase 4. Furthermore, the subject compounds and compositions are useful for the treatment of breast cancer and the like.

Claim (Index 33):
A method of screening KDM4 inhibitory activity of a KDM4 inhibitory compound, in primary breast cancer stem cells comprising the steps of\n obtaining breast tumor material; mechanically dissociating the tumor material; treating the tumor material with at least one DNAse, dispase, or thermolysin; diluting the tumor material in buffer; straining the dissociated treated tumor material to obtain tumor cells; optionally removing red blood cells with lysis buffer; washing the tumor cells in cell culture media; culturing the washed tumor cells in a stem cell enrichment medium comprising a 1:1 ratio of (a) liquid medium and (b) solid matrix, wherein (a) comprises:\n mammary epithelial basal medium, serum-free supplement, amphotericin, penicillin-streptomycin, epidermal growth factor, fibroblast growth factor, heparin, gentamicin, and Rho kinase inhibitor; \n incubating the stem cell enrichment culture at 37\u00b0 C. under low oxygen until the enriched cells proliferate as spheres; expanding the population of cells that proliferated as spheres in an expansion medium comprising (a) and (b) at a 98:2 ratio, to obtain expanded breast cancer stem cells; reculturing expanded breast cancer stem cells in stem cell enrichment medium comprising the KDM4 inhibitory compound; wherein the KDM4 inhibitory compound inhibits the ability of breast cancer stem cells to proliferate as spheres in comparison with breast cancer stem cells recultured without a KDM4 inhibitor.

Metadata:
- Claim Count in Document: 68.0
- Percentile: 90.0
- Lexical Diversity: 1.73171
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15792570', '15402100', '14443602', '13933609', '15475899']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.751430903272336
- 35 USC 102 Novelty (BERT): 0.51917077375196
- Combined Prediction Score: 0.7282048903202984
- Mean Citation Score: 256.860694
- Max Citation Score: 280.05762000000004
- Similarity Product: 160.7829374499214

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test